Home Cart Sign in  
Chemical Structure| 1236699-92-5 Chemical Structure| 1236699-92-5

Structure of Pimasertib
CAS No.: 1236699-92-5

Chemical Structure| 1236699-92-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AS7-03026 is a highly selective, potent, ATP non-competitive allosteric inhibitor of MEK1/2 with IC50 of 5 nM-2 μM in MM cell lines.

Synonyms: AS703026; MSC1936369B; SAR 245509

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pimasertib

CAS No. :1236699-92-5
Formula : C15H15FIN3O3
M.W : 431.20
SMILES Code : O=C(NC[C@H](O)CO)C1=CC=NC=C1NC2=CC=C(I)C=C2F
Synonyms :
AS703026; MSC1936369B; SAR 245509
MDL No. :MFCD16660676
InChI Key :VIUAUNHCRHHYNE-JTQLQIEISA-N
Pubchem ID :44187362

Safety of Pimasertib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Pimasertib

MAPK

Isoform Comparison

Biological Activity

Target
  • MEK1/2

    MEK1/2 (MM cell line), IC50:5 nM-2 μM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01992874 Neoplasms Phase 1 Completed - United States, Massachusetts ... More >> Please Contact U.S. Medical Information Located in Rockland, Massachusetts, United States Less <<
NCT01693068 N-Ras Mutated Locally Advanced... More >> or Metastasis Malignant Cutaneous Melanoma Less << Phase 2 Completed - -
NCT01713036 Locally Advanced or Metastatic... More >> Solid Tumors Less << PHASE1 COMPLETED 2014-07-31 Research Site, Budapest, Hunga... More >>ry Less <<
NCT01713036 Locally Advanced or Metastatic... More >> Solid Tumors Less << PHASE1 COMPLETED 2014-07-31 Research Site, Budapest, Hunga... More >>ry Less <<
NCT01992874 - Completed - -
NCT01693068 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.32mL

0.46mL

0.23mL

11.60mL

2.32mL

1.16mL

23.19mL

4.64mL

2.32mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories